Takeda, Intra-Cellular Ink Global Co-Development Deal For PDE1 Inhibitors For Schizophrenia
Deal for preclinical compounds includes undisclosed upfront payment and up to $750 million in milestones.
Deal for preclinical compounds includes undisclosed upfront payment and up to $750 million in milestones.